AstraZeneca

Empty AstraZeneca plant sized up by CDMO which may or may not be AGC Biologics
Empty AstraZeneca plant sized up by CDMO which may or may not be AGC Biologics
Fierce Pharma
AstraZeneca
Colorado
Japan
AGC Biologics
drug manufacturing
CDMO
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
AstraZeneca cans cancer pipeline efforts
AstraZeneca cans cancer pipeline efforts
Fierce Biotech
AstraZeneca
earnings
R&D
cancer
oncology
Flag link:
AstraZeneca's Chinese investment bank partner raises $229M for its own new fund — and it's all about the coronavirus
AstraZeneca's Chinese investment bank partner raises $229M for its own new fund — and it's all about the coronavirus
Endpoints
AstraZeneca
China
coronavirus
COVID-19
Flag link:
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
Fierce Biotech
diabetes
insulin
Mt Sinai
Novo Nordisk
Ozempic
Rybelsus
Victoza
Eli Lilly
Trulicity
AstraZeneca
Bydureon
Flag link:
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population
Endpoints
FibroGen
AstraZeneca
FDA
anemia
chronic kidney disease
roxadustat
Flag link:
AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
Fierce Pharma
AstraZeneca
Daiichi Sankyo
clinical trials
FDA
Enhertu
cancer
breast cancer
Flag link:
AstraZeneca expanding again in Australia, pledging $133M investment at Sydney site and adding 250 jobs
AstraZeneca expanding again in Australia, pledging $133M investment at Sydney site and adding 250 jobs
Fierce Pharma
AstraZeneca
Australia
New Zealand
drug manufacturing
asthma
COPD
Flag link:
Antibody-drug conjugates on the march
Antibody-drug conjugates on the march
Pharmaforum
antibody-drug conjugate
AstraZeneca
Daiichi Sankyo
Enhertu
Flag link:
Big pharma backed away from brain drugs. Is a return in sight?
Big pharma backed away from brain drugs. Is a return in sight?
BioPharma Dive
Big Pharma
Neuroscience
AstraZeneca
Bristol-Myers Squibb
GSK
Pfizer
Amgen
Flag link:
Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie
Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie
Xconomy
Allergan
AbbVie
AstraZeneca
M&A
Nestle
Flag link:
After a brief break, AstraZeneca is back at divesting — handing off hypertension meds for $350M
After a brief break, AstraZeneca is back at divesting — handing off hypertension meds for $350M
Endpoints
AstraZeneca
hypertension
Atnahs Pharma
Flag link:
Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study
Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study
Endpoints
AstraZeneca
breast cancer
Daiichi Sankyo
trastuzumab deruxtecan
gastric cancer
Flag link:
AstraZeneca makes case for use of blood thinner Brilinta in stroke patients
AstraZeneca makes case for use of blood thinner Brilinta in stroke patients
Endpoints
AstraZeneca
stroke
Brilinta
clinical trials
bloodthinners
Flag link:
After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune
After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune
Xconomy
AstraZeneca
MedImmune
Flag link:
AstraZeneca commits to being carbon negative by 2030
AstraZeneca commits to being carbon negative by 2030
Pharmaforum
AstraZeneca
climate change
carbon emissions
environmental concerns
Flag link:
Amid U.K. cutbacks, AstraZeneca plows $520M into manufacturing and R&D in France
Amid U.K. cutbacks, AstraZeneca plows $520M into manufacturing and R&D in France
Fierce Pharma
AstraZeneca
R&D
France
Brexit
UK
drug manufacturing
Flag link:
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
BioSpace
AstraZeneca
Imfinzi
orphan drugs
FDA
hepatocellular carcinoma
Flag link:
JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU
JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU
Fierce Pharma
Amarin
Vascepa
Epanova
AstraZeneca
Acasti
Europe
Flag link:
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Flag link:

Pages